Market accessOfficial

AIFA publishes class A and H medicine tables current to 30 June 2026

🇮🇹 AIFA · Mon 26 Oct 2026

Italy's medicines agency has issued updated lists of reimbursed and hospital-use products, ordered by active ingredient and trade name, to support prescribing by active substance.

The Italian Medicines Agency (AIFA) has made available its tables of class A and class H medicinal products dispensed by the National Health Service, reflecting the position at 30 June 2026. The tables are sorted by active ingredient and by trade name respectively.

AIFA says the publication enables prescribing by active ingredient, as required by Article 15, paragraph 11-bis, of Decree-Law 95 of 6 July 2012, converted into Law 135 of 7 August 2012. The agency describes the tables as a technical tool for all healthcare professionals.

The lists cover products on AIFA's transparency list, patent-protected medicines, and medicines whose patents have expired but for which substitution is not permitted. Unlike the transparency lists, the active-ingredient groupings in these tables do not set maximum reimbursement prices. Every pack of a medicinal product marketed at 30 June 2026 is included.

AIFA also flags one change in the class H prescribing table by active ingredient. To preserve historical data on equivalence groups, the equivalence code for the group amiodarone 150 mg/3 ml, five units for parenteral use, has been changed from "ADT" to "44°". The source notes that Amiodar (AIC 022033029) and Cordarone (AIC 025035027), which belong to the group, were classed in class A from 2000 to 2005. The available text is cut off at that point.

What it means for your team

  • Market-access and pricing teams should check product entries against the 30 June 2026 tables, which are not a price-setting instrument and carry no maximum reimbursement prices.
  • Teams that maintain internal databases or prescribing-system mappings should update the amiodarone parenteral class H equivalence code from "ADT" to "44°".
  • The publication is a reference update on reimbursement class and dispensing channel, with no safety or enforcement content.

Official source: AIFA ↗

Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.

More Market access All →